KOR

e-Article

The controversial role and therapeutic development of the m6A demethylase FTO in renal cell carcinoma
Document Type
article
Source
Subject
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Rare Diseases
Kidney Disease
Cancer
2.1 Biological and endogenous factors
Aetiology
m(6)A RNA demethylase
FTO
Renal cell carcinoma
Cancer progression
Prognosis
Inhibitors
Biochemistry and Cell Biology
Clinical Sciences
Oncology & Carcinogenesis
Biochemistry and cell biology
Oncology and carcinogenesis
Language
Abstract
Fat mass and obesity-associated (FTO) protein, the first m6A demethylase identified in 2011, regulates multiple aspects of RNA biology including splicing, localization, stability, and translation. Accumulating data show that FTO is involved in numerous physiological processes and is implicated in multiple cancers including renal cell carcinoma (RCC). However, the exact role of FTO in RCC remains controversial. Some studies demonstrated that decreased FTO expression was associated with aggressive clinical features and shorter overall survival in clear cell RCC (ccRCC) patients, while others found that FTO inhibition selectively reduced the growth and survival of VHL-deficient ccRCC cells in vitro and in vivo. Here, we review the evidence supporting either a promoting or suppressive role of FTO in kidney cancers, the mechanisms of action of FTO, and recent progress in developing FTO inhibitors.